You can help reduce undesirable changes in behavior and mood by suppressing your mare's estrous heat cycle with Regu-Mate® altrenogest. Within three days of the start of treatment, Regu-Mate will effectively suppress estrus in 95 percent of mares. It's important to note Regu-Mate cannot improve your mare's performance from what it is normally. Regu-Mate can only eliminate hormonal distractions so she can focus on you and perform more predictably.Add this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
* Regu-Mate effectively suppresses estrus in 95 percent of mares after 3 days of treatment. * When treatment is discontinued, mares exhibiting regular estrous cycles return to estrus within 4 to 5 days following treatment and continue to cycle normally.
* Regu-Mate can help alleviate moodiness and temperament changes associated with estrus. * It's easy to administer &ndash orally or top-dressed on grain.
Regu-Mate® altrenogest Solution 0.22% produces a progestational effect in mares.
Regu-Mate® altrenogest Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.
Regu-Mate® altrenogest Solution 0.22% is contraindicated for use in mares having a previous or current history of uterine inflammation i.e., acute, subacute, or chronic endometritis. Natural or synthetic gestagen therapy may exacerbate existing low-grade or smoldering&rdquo uterine inflammation into a fulminating uterine infection in some instances.
Various synthetic progestins, including altrenogest, when administered to rats during the embryogenic stage of pregnancy at doses manyfold greater than the recommended equine dose caused fetal anomalies, specifically masculinization of the female genitalia.
DOSAGE AND ADMINISTRATION:
While wearing protective gloves, remove shipping cap and seal replace with enclosed plastic dispensing cap. Remove cover from bottle dispensing tip and connect luer lock syringe without needle. Draw out appropriate volume of Regu-Mate solution. Note: Do not remove syringe while bottle is inverted as spillage may result. Detach syringe and administer solution orally at the rate of 1 mL per 110 pounds body weight 0.044 mg/kg once daily for 15 consecutive days. Administer solution directly on the base of the mare's tongue or on the mare's usual grain ration. Replace cover on bottle dispensing tip to prevent leakage. Excessive use of a syringe may cause the syringe to stick therefore, replace syringe as necessary.
WHICH MARES WILL RESPOND TO REGU-MATE® altrenogest SOLUTION 0.22%:
Extensive clinical trials have demonstrated that estrus will be suppressed in approximately 95% of the mares within three days however, the post-treatment response depended on the level of ovarian activity when treatment was initiated. Estrus in mares exhibiting regular estrus cycles during the breeding season will be suppressed during treatment these mares return to estrus four to five days following treatment and continue to cycle normally. Mares in winter anestrus with small follicles continued in anestrus and failed to exhibit normal estrus following withdrawal. Response in mares in the transition phase between winter anestrus and the summer breeding season depended on the degree of follicular activity. Mares with inactive ovaries and small follicles failed to respond with normal cycles post-treatment, whereas a higher proportion of mares with ovarian follicles 20 mm or greater in diameter exhibited normal estrus cycles post-treatment. Regu-Mate® altrenogest Solution 0.22% was very effective for suppressing the prolonged estrus behavior frequently observed in mares during the transition period February, March and April. In addition, a high proportion of these mares responded with regular estrus cycles post-treatment.
SPECIFIC USES FOR REGU-MATE® altrenogest SOLUTION 0.22%:
SUPPRESSION OF ESTRUS TO: 1. Facilitate attainment of regular cycles during the transition period from winter anestrus to the physiological breeding season. To facilitate attainment of regular cycles during the transition phase, mares should be examined to determine the degree of ovarian activity. Estrus in mares with inactive ovaries no follicles greater than 20 mm in diameter will be suppressed but these mares may not begin regular cycles following treatment. However, mares with active ovaries follicles greater than 20 mm in diameter frequently respond with regular post-treatment estrus cycles. 2. Facilitate management of the mare exhibiting prolonged estrus during the transition period. Estrus will be suppressed in mares exhibiting prolonged behavioral estrus either early or late during the transition period. Again, the posttreatment response depends on the level of ovarian activity. The mares with greater ovarian activity initiate regular cycles and conceive sooner than the inactive mares. Regu-Mate® altrenogest Solution 0.22% may be administered early in the transition period to suppress estrus in mares with inactive ovaries to aid in the management of these mares or to mares later in the transition period with active ovaries to prepare and schedule the mare for breeding. 3. Permit scheduled breeding of mares during the physiological breeding season. To permit scheduled breeding, mares which are regularly cycling or which have active ovarian function should be given Regu-Mate® altrenogest Solution 0.22% daily for 15 consecutive days beginning 20 days before the date of the planned estrus. Ovulation will occur 5 to 7 days following the onset of estrus as expected for nontreated mares. Breeding should follow usual procedures for mares in estrus. Mares may be regulated and scheduled either individually or in groups.
A 3-year well controlled reproductive safety study was conducted in 27 pregnant mares, and compared with 24 untreated control mares. Treated mares received 2 mL Regu-Mate® altrenogest Solution 0.22% /110 lb body weight 2x dosage recommended for estrus suppression from day 20 to day 325 of gestation. This study provided the following data: 1. In filly offspring all ages of treated mares, clitoral size was increased. 2. Filly offspring from treated mares had shorter interval from Feb. 1 to first ovulation than fillies from their untreated mare counterparts. 3. There were no significant differences in reproductive performance between treated and untreated animals mares & their respective offspring measuring the following parameters: * interval from Feb. 1 to first ovulation, in mares only. * mean interovulatory interval from first to second cycle and second to third cycle, mares only. * follicle size, mares only. * at 50 days gestation, pregnancy rate in treated mares was 81.8% 9/11 and untreated mares was 100% 4/4. * after 3 cycles, 11/12 treated mares were pregnant 91.7% and 4/4 untreated mares were pregnant 100%. * colt offspring of treated and control mares reached puberty at approximately the same age 82 & 84 weeks respectively. * stallion offspring from treated and control mares showed no differences in seminal volume, spermatozoal concentration, spermatozoal motility, and total sperm per ejaculate. * stallion offspring from treated and control mares showed no difference in sexual behavior. * testicular characteristics scrotal width, testis weight, parenchymal weight, epididymal weight and height, testicular height, width & length were the same between stallion offspring of treated and control mares.
For more information regarding this product please follow the link to the manufacturers website: www.regu-mate.com
REFERENCES: Shoemaker, C.F., E.L. Squires, and R.K. Shideler. 1989. Safety of Altrenogest in Pregnant Mares and on Health and Development of Offspring. Eq. Vet. Sci. 9 No. 2: 69-72. Squires, E.L., R.K. Shideler, and A.O. McKinnon. 1989. Reproductive Performance of Offspring from mares Administered Altrenogest During Gestation. Eq. Vet. Sci.9 No. 2: 73-76. WARNING: Do not use in horses intended for food.